Shares of Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biotech, were down by 11.7% as of 2:43 p.m. EDT on Wednesday. Over the four prior trading sessions, Corvus shares shot up by more than 230% in response to AstraZeneca's (NASDAQ: AZN) interim results from a midstage trial in patients with stage 3 non-small cell lung cancer (NSCLC). What sparked Corvus' jaw-dropping rally is the finding that Astra's own anti-CD73 antibody, known as oleclumab, significantly boosted response rates and progression-free survival in advanced NSCLC patients when combined with the blockbuster checkpoint inhibitor Imfinzi.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting